

HIHR-10 & EIT Health Investor Lounge Syllabus

Programme & Summary propositions

Co-organised by HIHR & EIT Health

June 1, 2022

VBO FEB - Brussels - Belgium

Participating academic institutions in the Benelux



Preferred partner



Silver partners



HIHR supporters

Content

Content.....	2
Programme HIHR pitch sessions , June 1, 2022	3
Programme EIT Health Investor Lounge , June 1, 2022	5
Overview Quickfire sessions , May 23 – June 9, 2022	6
Sponsors and supporters	8
Preferred partner.....	8
Silver sponsors	8
Supporters of HIHR	9
Contact	10

Programme HIHR pitch sessions, June 1, 2022



Morning programme

10th edition Healthy Ideas, Healthy Returns

09.30 *Welcome coffee*

10.00 *Opening* by the moderator of the day

Jeff Skinner, Executive Director Institute of Entrepreneurship and Private Equity (IECP), London Business School

Welcome

Clemens Ostrowicz, Chair HIHR / Team Leader Innovation and Partnering, University of Luxembourg - LCSB

J&J Innovation recap

Paul A Soons, Early Development Expert - Janssen Beerse Campus and J&J Innovation

10.20 *Pitch & Q&A session I*

*GlycoTherapeutics**, Therapeutics & Biotech, Radboud Innovation Science

Johan Pijnenborg, CEO / founder / inventor

*Sencilia B.V.**, MedTech & Diagnostics, University Medical Center Groningen (UMCG)

Amar Kamat, Co-founder / Managing Director

Amalus Therapeutics, Therapeutics & Biotech, UGent

Bart Roman, Scientific Founder

*Delta Diagnostics B.V.**, MedTech & Diagnostics, TNO

Bart de Boer, Founder / CTO

*Sella Therapies**, MedTech & Diagnostics, LURIS

Wouter van Furth, Co-founder / CEO

11.20 *Coffee break*

11.40 Continuation of the Pitch sessions

- See next page -

* Elevator pitch (see next page)

11.40 Pitch & Q&A session II

UPyTher BV, Therapeutics & Biotech, TU/e - The Gate
Geert van Almen, Managing Director / Founder

*HUSKK**, MedTech & Diagnostics, eHealth & Datascience, Vrije Universiteit Brussel
Lennert Vierendeels, Co-founder / CEO

*BiteOn**, MedTech & Diagnostics, Amsterdam University – VU
Martin Polman, CEO

*Protyon**, Digital Health & Datascience, Innovation Center at the UMC Groningen (UMCG)
Matthew Groves, Scientific Founder

*Orgonex**, Therapeutics & Biotech, Utrecht Holdings
Juliette van den Dolder, CEO

RespiQ, MedTech & Diagnostics, eHealth & Datascience, Unlock_ Leiden
Vitalii Vorkov, co-founder

12.50 Lunch

Pitches will last for a maximum of 10 min presentation, followed by 4 min Q&A (+1 min change).

*Elevator pitches** contain of a 5 min presentation plus 4 min Q&A (+1 min change).

Due to the density of the programme we must strictly adhere to the schedule.

In addition to these pitches, quickfire sessions are scheduled for each pitch-presentation during one of the following days, see schedule on page 7.

Summaries of the pitch propositions will be sent upon registration.

Programme EIT Health Investor Lounge, June 1, 2022



Afternoon programme
EIT Health Investor Lounge

INVESTOR
NETWORK



12.50 *Lunch*

14.15 *Opening afternoon programme* by the moderator of the day
Jeff Skinner, Executive Director Institute of Entrepreneurship and Private Equity (IECP), London Business School

Welcome

Bart Haex, Director Business Development & External Relations EIT Health Belgium Netherlands

14.25 *Experts insights – why investors like to invest locally*
Caroline Sai, Head of the EIT Health Investor Network
Isaac Middelman, Programme Director EIT Health, Venture Centre of Excellence
Laia Pascual, Investment Associate, Ship2B Ventures
Antoine d'Hollander, Investment Manager, Capricorn partners

15.15 *Pitch & Q&A session III*

iClusion, Digital health / other, the Netherlands

Edwin Klumper, Chairman of the board

Lumetry, Digital health & Datascience, Austria

Antonia Frizberg / Christian Neubauer, CEO & cofounder

Artiness, Digital health & Datascience, Italy

Filippo Piatti, CEO & cofounder

15.50 *Coffee break*

16.10 *Pitch & Q&A session IV*

ArthroSave B.V., MedTech, the Netherlands

Karianne Lindenhovius, CEO

MT Act, Therapeutics & Biotech, France

Siem van der Laan, CEO and co-founder

Sensius, Medtech, the Netherlands

Paul van den Biggelaar, CEO and co-founder

16.45 Closure of the day

17.00 *Networking drinks*

Summaries of the pitch propositions will be sent upon registration.

Overview Quickfire sessions, May 23 – June 9, 2022

HIHR offers new entrepreneurial teams/KTOs venture ideas, not pitch ready yet, the opportunity to test their idea / concept with investors, entrepreneurs and corporates in a 45 minute online session. We highly appreciate your feedback and encourage all investors to participate in these informal sessions.

These sessions for pre-mature projects will take place via MS Teams from 23 till 31 May, according to the following schedule:

Quickfire sessions

Subject to change

Quick fire sessions only		
Monday May 23	9:00 – 9:45	Encyotos BV - Growth platform for patient-derived microtumors for predictive in vitro drug testing NovelT - MedTech & Diagnostics
	12.00 – 12.45	AVR-3D - Improving Aortic Valve Repair - External 3D Annuloplasty Devices Sopartec S.A. – UCLouvain - MedTech & Diagnostics
	17.00 – 17.45	Flash Pathology - A new era in digital histology VU Amsterdam - MedTech & Diagnostics
Wednesday May 25	9:00 – 9:45	Protein design to solve organ cryopreservation - computational designed proteins to reduce freeze-thaw damage in cells, tissues and organs Wageningen University - Therapeutics & BioTech
	12.00 – 12.45	SupraVision - Regenerative therapy for blinding retinal disease Amsterdam UMCA - Therapeutics & BioTech
	17.00 – 17.45	DiaBub - Anti-chronic infectiousness chewing gum, Diamond Bubbles BIOPHARMACEUTICALS, B.V. Erasmus MC - Therapeutics & BioTech
Monday May 30	9:00 – 9:45	VivArt-X - Cell matrices for breast tissue regeneration Eindhoven University of Technology - MedTech & Diagnostics
	12.00 – 12.45	Rbosome - Improving the production of protein therapeutics Wageningen University & Research - Therapeutics & BioTech
	17.00 – 17.45	RetinaScope - Better screening in sight TNO - MedTech & Diagnostics
Tuesday May 31	9:00 – 9:45	Innofluidics - A microfluidics-based platform for blood analysis for personalized treatment of cancer The Gate (TU/e) - MedTech & Diagnostics
	12.00 – 12.45	MultiScreening - Implantable Devices enabling screening in vivo Maastricht University - MedTech & Diagnostics

Summaries of these Quickfire candidates will be sent upon registration.

If you are interested in joining a QF-session, but haven't received an Outlook invite yet, please send an email to clar-els@hihr.eu or jordi@hihr.eu.

We also offer these QF-sessions to pitchers to further discuss their investment opportunity more in depth. The schedule of these additional QF-sessions is as follows:

Quickfire sessions - after pitch

Subject to change

Quick fire sessions in addition to their pitch		
Thursday June 2	12.00 – 12.45	Upyther B.V. - <i>Slow-release hydrogel formulations for intraperitoneal therapy to treat peritoneal carcinomatosis</i> TU/e - The Gate - Therapeutics & BioTech
Friday June 3	9:00 – 9:45	Amalus Therapeutics - <i>First-in-class, selective small molecule inhibitors targeting a tumor-microenvironment cell type</i> UGent TechTransfer - MedTech & Diagnostics
	12.00 – 12.45	Sencilia B.V. - <i>Nature-inspired sensing solutions for improved healthcare</i> University Medical Center Groningen (UMCG) - MedTech & Diagnostics
	17.00 – 17.45	GlycoTherapeutics - <i>Carbohydrate-based next-generation anticancer drugs</i> Radboud Innovation Science - Therapeutics & BioTech
Tuesday June 7	9:00 – 9:45	Protyon - <i>Providing Structural Models For Personalised Medicine in Cancer</i> Innovation Center at the UMC Groningen (UMCG) - eHealth & Datascience
	12.00 – 12.45	BiteOn - <i>3D printed dental implants</i> Amsterdam University - VU - MedTech & Diagnostics
Wednesday June 8	9:00 – 9:45	HUSKK - <i>Next generation occupational exoskeletons Smart breath testing to radically improve COPD patients' everyday life</i> Vrije Universiteit Brussel - Ergonomy
	12.00 – 12.45	Delta Diagnostics B.V. - <i>Developing Biosensors for Life-Science R&D and Diagnostics</i> TNO - MedTech & Diagnostics
	17.00 – 17.45	Sella Therapies - <i>Powerful Pain Relief from the Body's Own Hormones</i> LURIS - MedTech & Diagnostics
Thursday June 9	9:00 – 9:45	Orgonex - <i>RPMotion - The new standard for organoid culture</i> Utrecht Holdings - Therapeutics & BioTech
	12.00 – 12.45	RespiQ - <i>Smart breath testing to radically improve COPD patients' everyday life</i> Unlock_ Leiden - MedTech & Diagnostics, eHealth & Datascience

If you are interested in joining a QF-session, but haven't received an Outlook invite yet, please send an email to clar-els@hihr.eu or jordi@hihr.eu.

Sponsors and supporters

Preferred partner

JNJ Innovation

[Johnson & Johnson Innovation](#) seeks to positively impact human health through innovation. We do this by helping entrepreneurs realize their dreams of creating healthcare solutions that improve people's lives around the world. We work side-by-side with innovators throughout their journey, providing a robust exchange of ideas and resources to support their success.



Our mission is to create the leading global innovation network to generate transformational healthcare solutions through value-creating partnerships, across all sectors: consumer, medical devices, pharmaceuticals and global public health.

We are comprised of a family of complementary teams that bring meaningful solutions and flexible approaches to support collaboration:

- Our [Innovation Centers](#) are regional hubs to access the best science and technology in the region. [Make the connection](#) if you are an entrepreneur or an early-stage consumer or medical device company, or a biopharmaceutical company seeking a collaboration to advance a program which is pre-proof of concept in humans.
- Our [JLABS network](#) of incubators support entrepreneurs launching consumer, medical device, or biopharmaceutical companies. [Make the connection](#) if you are seeking incubation space for your early-stage company, or seeking to expand your start-up through an exchange of ideas and collaboration.
- Our [JJDC, Inc.](#) strategic venture arm invests across all sectors and at all stages, from seed-level start-ups to Series B and beyond. [Make the connection](#) if you are seeking a strategic venture partner.
- Our [Janssen Business Development](#) team seeks to identify collaborative opportunities that will create transformative value for our partners and the world. [Make the connection](#) if you are an established pharmaceutical company, or mid-sized to large biotechnology company, and seek a collaboration or merger & acquisition discussion.

Feel free to contact our Benelux External Innovation Partnering leads [Paul Soons](#) or [Peter Roevens](#).

Silver sponsors

INKEF

INKEF Capital is a leading venture capital firm based in Amsterdam with a proven history in backing promising early stage companies in Europe.

INKEF takes pride in being a patient, long-term investor with the ability to support companies through several funding rounds all the way up to IPO.

From the early stages of being a technology or life science venture, INKEF

supports entrepreneurs building their ideas into successful international businesses. Inkef's investments include Onward Medical, Castor, iOnctura, Cardior and GitLAB, Remote among others. For more information please visit: www.inkef.com



Bioqube Ventures

Bioqube Ventures a specialist life sciences investment firm founded in 2016. The team consist out of investment professionals, sector experts and serial entrepreneurs that have a proven track record in successfully building and leading companies on their growth paths.

With a diversified investment strategy, including a venture creation model and industry guidance through selected strategic partnerships, Bioqube Ventures will exclusively invest in the most promising innovative science in Europe.

www.bioqubeventures.com



Arnold & Siedsma

We have over 100 years of experience in the legal protection of intellectual property of [inventions](#), [trademarks](#) and [designs](#). In addition to our offices in the Netherlands, Germany, Belgium and Switzerland, Arnold & Siedsma has an extensive global network of agents so that we can protect your rights anywhere in the world. Arnold & Siedsma has more than fifty in-house technical and legal experts with knowledge of all the important [innovative sectors](#), from [biotechnology](#) and [pharmaceutics](#) to [semiconductors](#) and [software](#). Our work in intellectual property varies: from assessing innovations, formulating and obtaining patent and trademark requests, protecting patent and trademark rights in case of transgression to providing strategic and operational advice.



Supporters of HIHR

NLC Health

Pain monitoring systems, ultrasound cancer detection, light therapy for newborns- these are just some of the life-changing technologies that NLC has brought to those in need- that would have otherwise been abandoned. Join us in nurturing healthtech ventures to advance health. www.nlc.health

V-Bio

V-Bio Ventures is an independent venture capital firm specialized in building and financing young, innovative life science companies. V-Bio Ventures was established in 2015 and works closely with Belgium-based VIB, one of the world's premier life science institutes. The fund invests throughout Europe in start-up and early-stage companies with high growth potential focusing on technologies that provide transformational improvements in the biopharmaceutical, pharmaceutical, diagnostics and agricultural sectors www.v-bio.ventures.

Thuja

Thuja Capital Management (Thuja) manages several venture capital funds aimed at building and scaling companies in the fields of (bio)pharmaceuticals, medtech and digital health. In addition to generating a financial return for its investors, Thuja's investments positively impact the health and well-being of patients. Thuja serves physicians and patients worldwide by providing capital to daring entrepreneurs with ground-breaking product concepts locally. For more information visit www.thujacapital.com.

Novalis

Novalis Biotech is an early stage venture capital investor in life sciences with a focus on "enabling technologies" such as research and manufacturing tools, bioinformatics, genomics, diagnostics and digital health. We strongly believe in capital light platform technology and close interaction with customers already early in the life of the company. Novalis invests from (pre-)seed stage to series A. www.novalis

Theodorus

Theodorus Funds are venture capital funds dedicated to early-stage tech investments. It invests mostly in Biotech, MedTech & AI companies with proprietary technologies. Besides its financing role, Theodorus also plays an active role in the development of its portfolio companies, guiding the company towards its success. Today, Theodorus holds 70M€ of assets under management, which helped fund >40 companies and create >700 M€ in value. Theodorus has offices in Montreal and Brussels. www.theodorus.be

Interested in becoming a sponsor or supporter as well ?
Just send an email to clar-els@hihr.eu to check out the options.

Contact

For additional information and inquiries please contact:

Healthy Ideas^{HIHR}
Healthy Returns



Funded by the
European Union

Claar-els van Delft
Mob +31 6 2848 0549
Claar-els@hihr.eu
www.hihr.eu

Nicolas van de Kerkhof
Mob + 31 6 38164617
nicolas.vandekerkhof@eithealth.eu
<https://eithealth.eu/>